104 related articles for article (PubMed ID: 38810147)
1. Sample-Treatment with the Virucidal β-Propiolactone Does Not Preclude Analysis by Large Panel Affinity Proteomics, Including the Discovery of Biomarker Candidates.
Beutgen VM; Bhagwat AM; Steitz AM; Reinartz S; Müller R; Graumann J
Anal Chem; 2024 Jun; 96(23):9332-9342. PubMed ID: 38810147
[TBL] [Abstract][Full Text] [Related]
2. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
3. The effect of chemical inactivation of bovine viral diarrhea virus with beta-propiolactone and binary ethyleneimine on plasma proteins and coagulation factors.
Refaie FM; Esmat AY; Mohamed AF; Mohamed WA
Egypt J Immunol; 2004; 11(2):9-20. PubMed ID: 16734113
[TBL] [Abstract][Full Text] [Related]
4. Treatment of influenza virus with beta-propiolactone alters viral membrane fusion.
Bonnafous P; Nicolaï MC; Taveau JC; Chevalier M; Barrière F; Medina J; Le Bihan O; Adam O; Ronzon F; Lambert O
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):355-63. PubMed ID: 24140008
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
Sasaki Y; Yoshino N; Sato S; Muraki Y
J Virol Methods; 2016 Sep; 235():105-111. PubMed ID: 27142111
[TBL] [Abstract][Full Text] [Related]
6. β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V; Prajeeth CK; Jendrny P; Twele F; Meller S; Pink I; Fathi A; Addo MM; Volk HA; Osterhaus A; von Köckritz-Blickwede M; Schulz C
J Virol Methods; 2023 Jul; 317():114733. PubMed ID: 37068591
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
[TBL] [Abstract][Full Text] [Related]
8. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.
Kulkarni R; Patil HP; Palkar S; Lalwani S; Mishra AC; Arankalle V
J Virol Methods; 2021 Jan; 287():113996. PubMed ID: 33126149
[TBL] [Abstract][Full Text] [Related]
10. Effect of the β-propiolactone treatment on the adsorption and fusion of influenza A/Brisbane/59/2007 and A/New Caledonia/20/1999 virus H1N1 on a dimyristoylphosphatidylcholine/ganglioside GM3 mixed phospholipids monolayer at the air-water interface.
Desbat B; Lancelot E; Krell T; Nicolaï MC; Vogel F; Chevalier M; Ronzon F
Langmuir; 2011 Nov; 27(22):13675-83. PubMed ID: 21981550
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of DNA by beta-propiolactone.
Perrin P; Morgeaux S
Biologicals; 1995 Sep; 23(3):207-11. PubMed ID: 8527119
[TBL] [Abstract][Full Text] [Related]
12. The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine.
Anderson MC; Baer H; Frazier DJ; Quinnan GV
J Allergy Clin Immunol; 1987 Dec; 80(6):861-8. PubMed ID: 3693763
[TBL] [Abstract][Full Text] [Related]
13. Surface modifications of influenza proteins upon virus inactivation by β-propiolactone.
She YM; Cheng K; Farnsworth A; Li X; Cyr TD
Proteomics; 2013 Dec; 13(23-24):3537-47. PubMed ID: 24123778
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of beta-propiolactone on mice, mouse-derived cell cultures, and Venezuelan equine encephalomyelitis virus.
HEARN HJ; DAWSON FW
Appl Microbiol; 1961 Jul; 9(4):278-82. PubMed ID: 13712596
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of viruses by beta-propiolactone in human cryo poor plasma and IgG concentrates.
Scheidler A; Rokos K; Reuter T; Ebermann R; Pauli G
Biologicals; 1998 Jun; 26(2):135-44. PubMed ID: 9811521
[TBL] [Abstract][Full Text] [Related]
16. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
Herrera-Rodriguez J; Signorazzi A; Holtrop M; de Vries-Idema J; Huckriede A
Vaccine; 2019 Mar; 37(12):1630-1637. PubMed ID: 30765167
[TBL] [Abstract][Full Text] [Related]
17. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus.
Kamaraj G; Lakshmi Narasu M; Srinivasan VA
Res Vet Sci; 2008 Dec; 85(3):589-94. PubMed ID: 18262212
[TBL] [Abstract][Full Text] [Related]
18. A rapid method for the inactivation of virus infectivity prior to assay for interferons.
Barrett AD; Hunt N; Dimmock NJ
J Virol Methods; 1984 Jul; 8(4):349-51. PubMed ID: 6206084
[TBL] [Abstract][Full Text] [Related]
19. Effect of beta-propiolactone on infectivity and haemagglutinin of the BK virus.
Pitko VM; Pyökäri P; Näse L; Mäntyjärvi R
Acta Pathol Microbiol Scand B; 1975 Apr; 83(2):141-4. PubMed ID: 168727
[TBL] [Abstract][Full Text] [Related]
20. Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus.
Morgeaux S; Tordo N; Gontier C; Perrin P
Vaccine; 1993; 11(1):82-90. PubMed ID: 8427040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
